Engineered T Cell Composition With Optimized CD4/CD8 Pooling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for manufacturing genetically engineered T cells, such as those with chimeric antigen receptors, are inefficient and lack an improved cell composition product.
Innovation Solution
A method involving pooling enriched CD4+ and CD8+ T cells at a specific ratio, incubating them under stimulating conditions with a stimulatory reagent, and introducing a recombinant receptor through transduction or transfection, all performed in serum-free media, to produce a composition of engineered T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used for manufacturing genetically engineered T cells, then the process is simpler, but the efficiency and success rate are low
Solution Approach 1:
The patent optimizes critical parameters including CD4:CD8 cell ratio (1:1 to 3:1), cell concentration (1×10^6 to 5×10^6 cells/mL), incubation time (18-48 hours), and stimulatory reagent concentrations to maximize transduction efficiency and cell viability while maintaining a manageable process framework
Solution Approach 2:
The method performs preliminary enrichment and isolation of CD4+ and CD8+ T cells before the main transduction process, and pre-optimizes the cell ratio and stimulation conditions to ensure high efficiency during the actual genetic engineering step
2Productivity
If cell concentration is increased to improve productivity, then more T cells are produced, but transduction efficiency decreases
Solution Approach 1:
The patent identifies an optimal cell concentration range (1×10^6 to 5×10^6 cells/mL) that balances productivity and transduction efficiency, and adjusts stimulatory reagent concentrations accordingly to maintain high efficiency across this range
3Reliability
If CD4+ and CD8+ T cells are pooled at optimal ratio, then transduction efficiency and cell viability are maximized, but the process requires precise ratio control
Solution Approach 1:
The patent establishes an optimal CD4:CD8 cell ratio range (1:1 to 3:1) that provides high reliability while allowing reasonable tolerance in ratio control, and optimizes cell concentration parameters to work effectively within this ratio range
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves a high success rate in producing genetically engineered T cells with efficient proliferation and expansion, ensuring a high percentage of viable cells expressing the recombinant receptor.
Implementation Method 1
stimulating conditions comprise the presence of a stimulatory reagent capable of activating one or more intracellular signaling domains of one or more components of a TCR complex and/or one or more intracellular signaling domains of one or more costimulatory molecules
Implementation Method 2
introducing a recombinant receptor into the cells through transduction or transfection
Implementation Method 3
introducing a recombinant receptor into the cells through transduction or transfection
Data Source
AI summary
The present disclosure provides methods for genetically engineering T cells, such as CD4+ T cells and/or CD8+ T cells, for use in cell therapy. In some aspects, the provided methods include one or more steps for pooling enriched CD4+ and CD8+ cells, such as at a 1:1 ratio, and then incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and/or cultivating the cells under conditions that promote proliferation and/or expansion. In some aspects, the provided methods are an efficient, reliable means to produce genetically engineered T cells with a high degree of success.